Published online before print March 31, 2008, doi: 10.1161/CIRCULATIONAHA.107.728022
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2008;117:1936-1944.)
© 2008 American Heart Association, Inc.
Coronary Heart Disease |
Complementary Roles for Biomarkers of Biomechanical Strain ST2 and N-Terminal Prohormone B-Type Natriuretic Peptide in Patients With ST-Elevation Myocardial Infarction
From the TIMI Study Group (M.S.S., D.A.M., C.P.C.) and Cardiovascular Division (M.S.S., D.A.M., L.J.H., C.M., C.P.C., R.T.L.), Brigham and Women’s Hospital, Department of Medicine, Harvard Medical School, Boston, Mass; Harvard Clinical Research Institute, Boston, Mass (W.G.); University of Freiburg, Freiburg, Germany (C.B.); Department of Laboratory Medicine and Pathology, Children’s Hospital, Boston, Mass (N.R.); and Cardiology Division and Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Boston (R.E.G.).
Correspondence to Marc S. Sabatine, MD, MPH, TIMI Study Group, Cardiovascular Division, Brigham and Women’s Hospital, 75 Francis St, Boston, MA 02115. E-mail msabatine{at}partners.org
Received July 13, 2007; accepted February 8, 2008.
Background— ST2 is a member of the interleukin-1 receptor family with a soluble form that is markedly upregulated on application of biomechanical strain to cardiac myocytes. Circulating ST2 levels are elevated in the setting of acute myocardial infarction, but the predictive value of ST2 independent of traditional clinical factors and of an established biomarker of biomechanical strain, N-terminal prohormone B-type natriuretic peptide (NT-proBNP), has not been established.
Methods and Results— We measured ST2 at baseline in 1239 patients with ST-elevation myocardial infarction from the CLopidogrel as Adjunctive ReperfusIon TherapY–Thrombolysis in Myocardial Infarction 28 (CLARITY-TIMI 28) trial. Per trial protocol, patients were to undergo coronary angiography after 2 to 8 days and were followed up for 30 days for clinical events. In contrast to NT-proBNP, ST2 levels were independent of clinical factors potentially related to chronic increased left ventricular wall stress, including age, hypertension, prior myocardial infarction, and prior heart failure; levels also were only modestly correlated with NT-proBNP (r=0.14). After adjustment for baseline characteristics and NT-proBNP levels, an ST2 level above the median was associated with a significantly greater risk of cardiovascular death or heart failure (third quartile: adjusted odds ratio, 1.42; 95% confidence interval, 0.68 to 3.57; fourth quartile: adjusted odds ratio, 3.57; 95% confidence interval, 1.87 to 6.81; P<0.0001 for trend). When both ST2 and NT-proBNP were added to a model containing traditional clinical predictors, the c statistic significantly improved from 0.82 (95% confidence interval, 0.77 to 0.87) to 0.86 (95% confidence interval, 0.81 to 0.90) (P=0.017).
Conclusions— In ST-elevation myocardial infarction, high baseline ST2 levels are a significant predictor of cardiovascular death and heart failure independently of baseline characteristics and NT-proBNP, and the combination of ST2 and NT-proBNP significantly improves risk stratification. These data highlight the prognostic value of multiple, complementary biomarkers of biomechanical strain in ST-elevation myocardial infarction.
CLINICAL PERSPECTIVE
Related Article:
-
Clinical Summaries
Circulation 2008 117: 1909.[Extract] [Full Text]
This article has been cited by other articles:
 |
|
 |
|
  P. R. Sinnaeve, J. A. Ezekowitz, K. Bogaerts, W. Droogne, R. Jarai, K. Huber, C. B. Granger, W. J. Desmet, P. W. Armstrong, F. J. Van de Werf, et al. Reperfusion before percutaneous coronary intervention in ST-elevation myocardial infarction patients is associated with lower N-terminal pro-brain natriuretic peptide levels during follow-up, irrespective of pre-treatment with full-dose fibrinolysis Eur. Heart J., September 2, 2009; 30(18): 2213 - 2219. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. R. deFilippi and S. L. Seliger Biomarkers for prognostication after acute coronary syndromes: new times and statistics. J. Am. Coll. Cardiol., July 21, 2009; 54(4): 365 - 367. [Full Text] [PDF]
|
|
|
|
 |
|
 R. V. Shah, A. A. Chen-Tournoux, M. H. Picard, R. R.J. van Kimmenade, and J. L. Januzzi Serum Levels of the Interleukin-1 Receptor Family Member ST2, Cardiac Structure and Function, and Long-Term Mortality in Patients With Acute Dyspnea Circ Heart Fail, July 1, 2009; 2(4): 311 - 319. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Kuhn, T. Addona, H. Keshishian, M. Burgess, D.R. Mani, R. T. Lee, M. S. Sabatine, R. E. Gerszten, and S. A. Carr Developing Multiplexed Assays for Troponin I and Interleukin-33 in Plasma by Peptide Immunoaffinity Enrichment and Targeted Mass Spectrometry Clin. Chem., June 1, 2009; 55(6): 1108 - 1117. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Bartunek, L. Delrue, F. Van Durme, O. Muller, F. Casselman, B. De Wiest, R. Croes, S. Verstreken, M. Goethals, H. de Raedt, et al. Nonmyocardial production of ST2 protein in human hypertrophy and failure is related to diastolic load. J. Am. Coll. Cardiol., December 16, 2008; 52(25): 2166 - 2174. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W.H. W. Tang and G. S. Francis The Year in Heart Failure J. Am. Coll. Cardiol., November 11, 2008; 52(20): 1671 - 1678. [Full Text] [PDF]
|
|
|
|
|
|
J. Diez Serum Soluble ST2 as a Biochemical Marker of Acute Heart Failure: Future Areas of Research J. Am. Coll. Cardiol., October 28, 2008; 52(18): 1466 - 1467. [Full Text] [PDF]
|
|